Wha Bin Im

This inventor holds 37 USPTO granted patents and 17 published patent applications, plus 3 CIPO patents and 20 EPO patents, primarily in Sphingosine Receptor Modulators. Top assignee: Allergan, Inc.. Active years: 2008-2019.

USPTO Granted Patents = 37 (Patent Applications = 17)

% Patents Active = 56.8

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 20 (Patent Applications = 39)

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 164(Granted Patents)

Company Filing History:

37 out of 2,287

Allergan, Inc.

patents

Years Active: 2008-2019

Loading Chart...

Areas of Expertise:

Sphingosine-1 Phosphate

Prodrugs

Soft Tissue Replacement

Oxadiazole Derivatives

Pyrazole Derivatives

Azetidine Derivatives

Bicyclic Compounds

Therapeutic Lactams

Inflammatory Bowel Disease

Quaternary Ammonium

Central Corneal Thickening

Modulators

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10329284 - Ester prodrugs of gamma-lactams and their use (2019-06-25),

2. 9981938 - Quaternary ammonium alkyl esters as stable prodrugs (2018-05-29),

3. 9371296 - Bicyclic 1,3,4-oxadiazole derivatives as sphingosine-1-phosphate receptors' modulators (2016-06-21),

4. 9334262 - Methods of treating soft tissue defects (2016-05-10),

5. 9108993 - Pyrazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2015-08-18),

6. 9090595 - Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes (2015-07-28),

7. 9079864 - Modulators of S1P receptors (2015-07-14),

8. 9062030 - Pyrazole azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2015-06-23),

9. 9005605 - Compositions and soft tissue replacement methods (2015-04-14),

10. 8987471 - Substituted dihydropyrazoles as sphingosine receptor modulators (2015-03-24),

11. 8987467 - Substituted pyrazole azetidines as sphingosine receptor modulators (2015-03-24),

12. 8946195 - Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators (2015-02-03),

13. 8926963 - Compositions and soft tissue replacement methods (2015-01-06),

14. 8900571 - Compositions and soft tissue replacement methods (2014-12-02),

15. 8894992 - Compositions and soft tissue replacement methods (2014-11-25),

Title: Wha Bin Im: Innovator in Ocular Therapeutics

Introduction

Wha Bin Im is a prominent inventor based in Irvine, CA, known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 37 patents, he has established himself as an innovator in the treatment of ocular diseases.

Latest Patents

Among his latest patents are two noteworthy inventions. The first is titled "Ester prodrugs of gamma-lactams and their use." This patent describes ester prodrugs of gamma-lactam compounds that are valuable in treating ocular diseases, including glaucoma and macular degeneration. The second patent, "Quaternary ammonium alkyl esters as stable prodrugs," discloses compounds that are aimed at lowering intraocular pressure (IOP) and promoting hair growth. Both patents highlight his focus on addressing critical health issues through innovative solutions.

Career Highlights

Wha Bin Im is currently employed at Allergan, Inc., a leading pharmaceutical company known for its dedication to developing advanced treatments in eye care and aesthetics. His time at Allergan has been marked by breakthroughs in drug formulation and delivery systems that have the potential to improve patient outcomes significantly.

Collaborations

Throughout his career, Wha Bin Im has collaborated with esteemed colleagues such as Ken Chow and Dennis E Van Epps. These partnerships have fostered a dynamic environment for innovation, allowing the integration of diverse expertise in developing cutting-edge therapeutic solutions.

Conclusion

Wha Bin Im's impressive number of patents and his work on groundbreaking treatments demonstrate his commitment to advancing ocular health. His innovative approaches continue to inspire progress in the pharmaceutical industry, ultimately benefitting patients in need of effective therapies.